Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 70, or age ≥ 60 ineligible for treatment with standard induction chemotherapy (based on physician discretion or patient refusal), with a new diagnosis of AML based on World Health Organization Classification.~2. Eastern Cooperative Oncology Group Performance Status of 0-2~3. Cardiac ejection fraction ≥45%~4. Males are eligible to enter and participate in the study if they have either had a prior vasectomy or agree to avoid sexual activity or use adequate contraception from screening through two months post the last dose of decitabine~Exclusion Criteria:~1. Patients with acute promyelocytic leukemia~2. Life expectancy ≤3 months~3. Prior use of any hypomethylating agent or cytarabine~4. Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy~5. Serum creatinine \> 2x upper limit of normal~6. Aspartate aminotransferase (AST),alanine aminotransferase (ALT), or total bilirubin \> 5x upper limit of normal~7. History of psychiatric disorder which may compromise compliance with the protocol or which does not allow for appropriate informed consent~8. Patient may not be receiving any other antineoplastic agents (hydroxyurea is allowed)~9. Concurrent malignancy. Exception: Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled.~10. Evidence of severe or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, hepatic, renal, or cardiac disease).

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- decitabine and cytarabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).